Evidence map›Paper›PMID 35647674›Full record

ReviewCell biochemistry and function2022

Application of exosomes for the alleviation of COVID-19-related pathologies.

Aysa Rezabakhsh, Mahdi Mahdipour, Alireza Nourazarian, Paria Habibollahi, Emel Sokullu, Çigir Biray Avci, Reza Rahbarghazi

Open access · greenAbstract readReview
In one paragraph

Review in Cell biochemistry and function, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Aysa RezabakhshCardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mahdi MahdipourStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Alireza NourazarianDepartment of Basic Medical Sciences, Khoy University of Medical Sciences, Khoy, Iran.
Paria HabibollahiDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Emel SokulluKoç University Research Center for Translational Medicine (KUTTAM), Istanbul, Sariyer, Turkey.
Çigir Biray AvciDepartment of Medical Biology, Faculty of Medicine, Ege University, Izmir, Turkey.ORCID http://orcid.org/0000-0001-8251-4520
Reza RahbarghaziStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID http://orcid.org/0000-0003-3864-9166
Tabriz University of Medical Sciences · IREge University · TRIslamic Azad University, Khoy Branch · IRKoç University · TR

Funding

National Institute for Medical Research Development (NIMAD)NIMADTabriz University of Medical Sciences
6 · The paper itself

Abstract

The pandemic of COVID-19 caused worldwide concern. Due to the lack of appropriate medications and the inefficiency of commercially available vaccines, lots of efforts are being made to develop de novo therapeutic modalities. Besides this, the possibility of several genetic mutations in the viral genome has led to the generation of resistant strains such as Omicron against neutralizing antibodies and vaccines, leading to worsening public health status. Exosomes (Exo), nanosized vesicles, possess several therapeutic properties that participate in intercellular communication. The discovery and application of Exo in regenerative medicine have paved the way for the alleviation of several pathologies. These nanosized particles act as natural bioshuttles and transfer several biomolecules and anti-inflammatory cytokines. To date, several approaches are available for the administration of Exo into the targeted site inside the body, although the establishment of standard administration routes remains unclear. As severe acute respiratory syndrome coronavirus 2 primarily affects the respiratory system, we here tried to highlight the transplantation of Exo in the alleviation of COVID-19 pathologies.

Indexed as

COVID-19ExosomesCytokinesHumansSARS-CoV-2CytokinesCOVID-19exosomesparacrine interactionregenerative potentialstem celltherapeutic effects

Identifiers

PMID35647674
PMCPMC9348296
OpenAlexW4281662738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.